{
  "id": 1730682,
  "title": "Earnings call transcript: Basilea lifts H1 2026 outlook as stock jumps 8.7%",
  "url": "https://urgent.news/2026/08/18/earnings-call-transcript-basilea-lifts-h1-2026-outlook-as-stock-jumps",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T14:51:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-basilea-lifts-h1-2026-outlook-as-stock-jumps-87-93CH-4865661"
  },
  "original_language": "en",
  "account": "Basilea Pharmaceutica reported a 14% increase in first-half 2026 revenue to CHF 119 million. Operating profit rose 32% to CHF 31.6 million, driven by strong demand for their antifungal drug Cresemba and growing royalty income. The company raised full-year guidance for both revenue and operating profit. Cresemba sales reached CHF 782 million, up 27% year-over-year. Royalty income grew 11% to CHF 57.8 million, with milestone and upfront payments totaling CHF 4.7 million. Product revenue grew to CHF 30 million. Other revenue, mainly from BARDA and CARB-X reimbursements, was CHF 26.7 million. Operating expenses increased due to R&D investments, but profit growth outpaced revenue growth. Cash and cash equivalents doubled to CHF 176 million. The company's operating cash flow was CHF 19 million. Basilea lifted its full-year 2026 revenue and operating profit forecasts, expecting a 15% revenue increase and 40% operating profit growth. Executives highlighted Cresemba's strong performance, with sales now near $800 million annually and growing 29% year-over-year. The company also shared pipeline opportunities, including fosmanogepix and ceftibuten-ledaborbactam, which could generate peak sales of about $1.5 billion.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Hesai Q2 2026 revenue rises 22% as stock falls premarket",
        "url": "https://urgent.news/2026/08/18/earnings-call-transcript-hesai-q2-2026-revenue-rises-22-as-stock",
        "published": "2026-08-18T13:19:09.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}